Integra Lifesciences Holdings (IART) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
85.5mn → 76.7mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
−22.0% YoY in FY25 · 5.0% of revenue.
$0.2M returned vs $−31.1M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-32¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 61.2% → 50.9%. Net margin -31.6% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,656.8 | 1,635.2 | 1,610.5 | 1,541.6 | 1,557.7 | 1,542.4 | ▲1.5% | +1.5% |
Cost of revenue | 789.3 | 803.6 | 728.5 | 656.8 | 587.4 | 597.8 | ▲10.3% | +7.7% |
Gross profit | 867.5 | 831.6 | 882.1 | 884.7 | 970.3 | 944.6 | ▼5.7% | −3.1% |
Research & development | 94.4 | 99.0 | 115.4 | 104.2 | 101.2 | 93.1 | ▼14.2% | +1.6% |
Selling, general & admin | 685.2 | 699.7 | 717.0 | 656.6 | 616.3 | 637.4 | ▼2.4% | +2.4% |
Total operating expenses | 794.8 | 1,325.0 | 853.6 | 773.2 | 731.4 | 747.4 | ▲55.2% | +15.4% |
Operating incomefeeds ROC rank | 72.7 | −493.4 | 28.4 | 111.5 | 238.9 | 197.2 | — | — |
Other income, net | −50.4 | −70.1 | −46.6 | −30.5 | −25.0 | 17.4 | — | — |
Pretax income | 22.3 | −563.5 | −18.2 | 81.1 | 213.9 | 214.7 | ▼2989.9% | — |
Income tax | 9.3 | −47.0 | −11.3 | 13.3 | 33.3 | 45.6 | ▼316.4% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 13.0 | −516.5 | −6.9 | 67.7 | 180.6 | 169.1 | ▼7337.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 0.16 | −6.74 | −0.09 | 0.84 | 2.16 | 1.98 | ▼7388.9% | — |
Diluted shares (mn) | 78.58 | 76.67 | 77.01 | 80.34 | 83.52 | 85.48 | ▼0.4% | −2.7% |
| Margins | ||||||||
Gross margin30th pct in Healthcare | 52.4% | 50.9% | 54.8% | 57.4% | 62.3% | 61.2% | ▼3.9pp | −10.4pp |
Operating margin | 4.4% | −30.2% | 1.8% | 7.2% | 15.3% | 12.8% | ▼31.9pp | −43.0pp |
Net margin41st pct in Healthcare | 0.8% | −31.6% | −0.4% | 4.4% | 11.6% | 11.0% | ▼31.2pp | −42.5pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Integra Lifesciences Holdings' revenue last fiscal year?
Integra Lifesciences Holdings reported revenue of $1,635.2M in fiscal 2025, up 1.5% from fiscal 2024.
What was Integra Lifesciences Holdings' net income?
Integra Lifesciences Holdings reported net income of −$516.5M in fiscal 2025, a net margin of −31.6%.

